Thalidomide-NH-PEG2-C2-NH-Boc

Cat. No.: HY-130853

CAS No.: 2097509-40-3

Molecular Formula: $C_{24}H_{32}N_4O_8$

Molecular Weight: 504.53

Target: E3 Ligase Ligand-Linker Conjugates

Pathway: PROTAC

Storage: -20°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (198.20 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.9820 mL	9.9102 mL	19.8204 mL
5 mM	0.3964 mL	1.9820 mL	3.9641 mL
10 mM	0.1982 mL	0.9910 mL	1.9820 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (4.96 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (4.96 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Thalidomide-NH-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a PEG linker used for dBRD9 (compound 6) synthesis. dBRD9 is a selective BRD9 probe PROTAC degrader for the study of BAF complex biology[1].

IC_{50} & Target

Cereblon

In Vitro

dBRD9 (0-1 μM) exerts a potent anti-proliferative effect, exceeding non-degrading probe potencies in excesses of 10 to 100 fold[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. David Remillard, et al. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.2017 May 15;56(21):5738-5743.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA